GlassScriptPhysician profile
Katherine Olmstead
NPI 1699211029
$2,059.62
in general payments reported to CMS, 2019-2025
26 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $432 · 2024: $462 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.98 | 2023-2025 | |
| Novo Nordisk INC | $309.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $231.56 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $152.95 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Ars Pharmaceuticals Operations, INC. | $149.02 | 2025 | Neffy |
| Pfizer INC. | $100.37 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.71 | 2025 | Trintellix |
| Astellas Pharma US INC | $59.45 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $56.66 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Daiichi Sankyo INC. | $55.48 | 2023-2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $46.93 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Exeltis, USA INC. | $40.99 | 2025 | Slynd |
| Pharmacosmos Therapeutics INC. | $34.14 | 2025 | Monoferric |
| Corium, LLC | $34.00 | 2024 | Azstarys |
| Exact Sciences Corporation | $31.18 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $24.74 | 2025 | Quviviq |
| Hologic Sales and Service, LLC | $23.31 | 2025 | Aptima |
| Eisai INC. | $18.37 | 2025 | |
| Lilly USA, LLC | $18.20 | 2024 | Jardiance |
| Millicent US INC | $17.66 | 2025 | Femlyv, Intrarosa |
| Lundbeck LLC | $16.68 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.15 | 2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $15.80 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $15.43 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.43 | 2023 | Verquvo, Belsomra |
| Amgen INC. | $13.49 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Olmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.